

Pioneering Prescription Digital Therapeutics for Treating Cardiometabolic Diseases

THIRD QUARTER 2023 EARNINGS
CONFERENCE CALL

NOVEMBER 9, 2023

Better⁺
THERAPEUTICS



AspyreRx™ 



Introduction



Mark Heinen
Chief Financial Officer

Better Therapeutics Team



Frank Karbe

President &
Chief Executive Officer



Mark Heinen

Chief Financial Officer



Mark Berman, MD

Chief Medical Officer



Diane Gomez-Thinnes

Chief Commercial Officer

Disclaimer

This presentation (“Presentation”) is for informational purposes only. The information contained herein does not purport to be all-inclusive and neither Better Therapeutics, Inc. (“BetterTX” or the “Company”) nor any of its respective affiliates nor any of its or their control persons, officers, directors, employees or representatives makes any representation or warranty, express or implied, as to the accuracy, completeness or reliability of the information contained in this Presentation. You should consult your own counsel and tax and financial advisors as to legal and related matters concerning the matters described herein, and, by accepting this Presentation, you confirm that you are not relying upon the information contained herein to make any decision. The reader shall not rely upon any statement, representation or warranty made by any other person, firm or corporation in making its investment or decision to invest in the Company. Neither the Company nor any of its respective affiliates nor any of its or their control persons, officers, directors, employees or representatives, shall be liable to the reader for any information set forth herein or any action taken or not taken by any reader, including any investment in shares of the Company.

Certain information contained in this Presentation relates to or is based on studies, publications, surveys and the Company’s own internal estimates and research. In addition, all of the market data included in this Presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the Company believes its internal research is reliable, such research has not been verified by any independent source. This meeting and any information communicated at this meeting are strictly confidential and should not be discussed outside your organization.

Forward-Looking Statements.

Certain statements in this Presentation may be considered forward-looking statements, within the meaning of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are typically identified by words such as “plan,” “believe,” “expect,” “anticipate,” “intend,” “outlook,” “estimate,” “forecast,” “project,” “continue,” “could,” “may,” “might,” “possible,” “potential,” “predict,” “should,” “would” and other similar words and expressions, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements in this Presentation include, but are not limited to, statements regarding the delivery of cognitive behavioral therapy and/or prescription digital therapeutics by the Company to address the root causes of type 2 diabetes and other cardio metabolic diseases, development of a proprietary platform and software-based solutions for treatment of type 2 diabetes, heart disease and other conditions, achievement of changes in neural pathways of the brain and lasting changes in behavior through cognitive behavioral therapy delivered by the Company’s PDTs, the capability of the Company to address the underlying causes of certain diseases and its related potential to improve patient health while lowering healthcare costs, the results of the trial of real-world evidence studies in patients with type 2 diabetes, the Company's plans regarding FDA submissions, plans and expectations regarding the commercialization of AspyreRx, expectations related to the potential benefits of AspyreRx and CBT and its potential treatment applications, the Company's plans regarding the research and advancement of its product candidates for additional treatments and other upcoming milestones, expectations related to the interest of healthcare providers and payers in PDTs, including AspyreRx, the timing of and expectations related to the Company's engagement with Veterans Affairs and other payers, and any potential agreements with payers, the future financial stability, strength, or success of the Company, and legislative developments affecting PDTs and the outcome of such developments, the Company’s expectations about potential business development, partnerships and future financings, expectations and assumptions regarding the addressable market, covered lives, market penetration, prescription numbers and fill rates for AspyreRx, and statements related to its cash runway and long-term strategy, plans and expectations, among others. These forward-looking statements are based on the current expectations of the management of the Company and are inherently subject to uncertainties and changes in circumstances and their potential effects and speak only as of the date of such statement. There can be no assurance that future developments will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements including: risks related to the Company's business, such as the willingness of the FDA to authorize PDTs for commercial distribution and insurance companies to reimburse their use, market acceptance of PDTs, including AspyreRx, the risk that the results of previously conducted studies will not be repeated or observed in ongoing or future studies involving our product candidates and other risks and uncertainties included under the header “Risk Factors” in the Company’s quarterly report on Form-10-Q for the fiscal quarter ended September 30, 2023 filed with the Securities and Exchange Commission (“SEC”) on November 09, 2023, and those that are included in any of the Company’s subsequent filings with the SEC.



Opening Remarks




Frank Karbe

President & Chief Executive Officer

Empowering People with Type 2 Diabetes

AspyreRx™ is the first cognitive behavioral therapy app to receive FDA authorization as a Class II medical device to treat type 2 diabetes in adults



Progress Towards Resolving our 3 Key Risks

1

Regulatory



2

Commercial Launch Execution

Underway

3

Financing

Underway

Key Milestones Accomplished in Q3 and October 2023

1. Obtained FDA Authorization for AspyreRx

The first prescription-only digital therapeutic treatment indicated to provide cognitive behavioral therapy to adults with type 2 diabetes

2. Completed Enrollment in AspyreRx Real-world Evidence Program

1,000 participants enrolled in studies evaluating the long-term effectiveness of AspyreRx in type 2 diabetes

3. New Patent Issued

"Managing lifestyle and health interventions with predictive analytics" was issued in the European Union

4. Commercially Launched AspyreRx

Healthcare providers in the U.S. have begun prescribing and patients are active in treatment

Key Milestones Accomplished in Q3 and October 2023

5. LivVita Liver Study Results Published in *Gastro Hep Advances*

Authors concluded the totality of positive efficacy, safety, and usability data indicates the potential of Better Therapeutics' digitally delivered CBT to help address the significant unmet clinical needs in MASLD/MASH

6. New Data from Subgroup Analysis in T2D

New data from a subgroup analysis shows superior clinical outcomes with concurrent use of Aspyrerx and GLP-1 receptor agonists to treat type 2 diabetes

7. Showcased AspyreRx at First Promotional Meeting

Participated in the American College of Lifestyle Medicine's 2023 Annual Meeting with ~3,000 healthcare professionals

8. Raised Additional Capital

Utilized At-the-market facility to raise an additional \$2.9M in capital to support commercialization efforts



Our focus for the remainder of the year is to lay the foundations for a successful commercial launch



To ensure eligible patients have affordable access to AspyreRx, we are offering a self-pay option for a limited period



We expect to provide revenue guidance once we have at least 2 - 3 quarters of commercial experience



Commercial Update




Diane Gomez-Thinnes
Chief Commercial Officer

AspyreRx Now Commercially Available

Featured in The AARP Magazine

Coverage in 20+ publications

Debut at ACLM 2023



Progress with Payers

21

Payer meetings since FDA authorization in July

13

Progressed to clinical presentations

7

Advanced to next steps



Submitted Comparative Effectiveness Analysis for peer-review publication




Submitted application to Federal Supply Schedule (FSS) for VA access



Published price on all major Compendia

Commenced Implementation of Go-to-Market Strategy

Heatmap showing concentration of high prescribing providers in initial target geographies



Commenced deploying field sales personnel in targeted geographies



Refreshed data identified 4,300 innovator and early adopter HCPs covering ~15 million scripts/year



200+ leads from ACLM meeting


Notable Industry Advancements



- FDA announced formation of a Digital Health Advisory Committee to support safe and effective regulation of digital health technologies while encouraging innovation
- FDA issued draft guidance titled 'Regulatory Considerations for Prescription Drug Use-Related Software' to consider drug & digital therapeutic combination labeling



- House Energy and Commerce(E&C) Committee held a sub-committee hearing in which they reviewed the Access to Prescription Digital Therapeutics bill
- A Congressional Budget Office (CBO) score has been requested



AspyreRx™ 

AspyreRx is commercially available and healthcare providers in the U.S. are prescribing the treatment.



Financial Review



Mark Heinen
Chief Financial Officer

Financial Highlights

(Unaudited, in millions, except per share data)

	Q3 2023	Q3 2022
Research and development	\$1.8	\$5.5
Sales and marketing	1.4	1.6
General and administrative	2.1	4.0
Total operating expenses	5.3	11.0
Interest expense	0.5	0.4
Provision for income taxes	-	-
Net loss	\$(5.9)	\$(11.4)
Loss per share	\$(0.15)	\$(0.48)
	Sep 30, 2023	
Cash and cash equivalents	\$6.6	
Pro forma cash and cash equivalents ⁽¹⁾	\$9.5	

⁽¹⁾ Pro forma cash and cash equivalents includes \$2.9 million in gross proceeds from our ATM facility in October 2023.



Closing Comments



Frank Karbe

President & Chief Executive Officer

Key Milestones for the Remainder of 2023

- 1 Obtain Commercial Payer Coverage for AspyreRx
- 2 Submit Request for Breakthrough Device Designation in MASLD/MASH
- 3 Announce Business Development Partnership
- 4 Further Strengthen Financial Position

Q&A Panel



Frank Karbe

President &
Chief Executive Officer



Mark Heinen

Chief Financial Officer



Mark Berman, MD

Chief Medical Officer



Diane Gomez-Thinnes

Chief Commercial Officer